FORT WORTH, TX / ACCESSWIRE / September 17, 2018 / WNDM Medical Inc. (OTCQB: WNDM), announced today it will host a call with shareholders and other interested parties on Wednesday, September 19, 2018 from 3:00 pm to 4:00 pm CDT to provide information on the previously announced transaction with The Catalyst Group ("Catalyst"). WNDM and Catalyst entered into definitive agreements to continue WNDM's current operations through joint 50% ownership in a newly formed limited liability company, Cellerate, LLC. The original press release regarding this transaction is available on WNDM's website at

John Siedhoff, WNDM Chairman, Michael Carmena, WNDM CEO, and Michael McNeil, WNDM CFO, will answer questions received via email from the investor community.

Please email questions in advance to If time allows, additional questions emailed during the call will be answered in the order received. The names of people submitting questions will be kept anonymous unless specifically requested otherwise.

Interested parties may access the conference call by dialing (515) 739-6170 and using access code 627062#.

About WNDM Medical Inc.

With its No. 1 goal of improving patient outcomes, WNDM Medical Inc. develops, markets and distributes biotechnology products to physicians, hospitals, and clinics. It has a strong history of developing long-term strategic partnerships with a focus on products that fuse nature and science with medicine. Its primary products are in the $11 billion U.S. consumable medical device market and the $1.5 billion biomaterials market. WNDM Medical sells and distributes CellerateRX®/CRXα® Surgical Activated Collagen® Adjuvant and HemaQuell® Resorbable Bone Hemostat. For more information, visit

Information about Forward-Looking Statements

The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations

SOURCE: WNDM Medical Inc.

View source version on